ACD-856
Cognition, Neurotrophic
Investigational compound in early clinical development; pharmacokinetics not publicly published.
In short
- A positive allosteric modulator of Trk receptors, intended to potentiate neurotrophin signalling (NGF, BDNF).
- Developed by Alzecure Pharma for cognitive disorders including Alzheimer disease.
- Has completed phase 1 studies in healthy volunteers, which is real human data.
- Detailed pharmacokinetics and any efficacy results are not publicly published.
- Investigational, not approved anywhere.
Structure
An investigational small molecule from Alzecure. PubChem has no public entry under this development code as of this review date.
How it works
Trk receptors (TrkA, TrkB, TrkC) mediate signalling from the neurotrophins NGF, BDNF, and NT-3, driving neuronal survival, differentiation, and synaptic plasticity. BDNF/TrkB signalling in particular is central to hippocampal plasticity and is reduced in Alzheimer disease and depression.
Direct neurotrophin administration has repeatedly failed as a therapy — the proteins are large, do not cross the blood-brain barrier, and produce dose-limiting effects.
ACD-856 is a small-molecule positive allosteric modulator: rather than activating Trk receptors, it amplifies signalling when the endogenous neurotrophin is present. This is the same design philosophy as TAK-653 at the AMPA receptor, and it is a sensible response to the failures of direct agonism.
What the research shows
Phase 1 studies in healthy volunteers have been completed, with the company reporting good tolerability and effects on EEG markers consistent with target engagement.
Preclinical work reports procognitive effects in animal models.
No phase 2 efficacy results are publicly available as of this review, and detailed data has largely been communicated through company announcements rather than peer-reviewed publication.
Dosing in the literature
Figures below are quoted from published studies, with the species or population they were measured in. They are records of what was studied, not recommendations.
| Studied in | Amount | Route | Source |
|---|---|---|---|
| Human — phase 1 single and multiple ascending dose studies | Dose ranges not fully published; see trial records | oral | PubMed |
Commonly reported ranges
These are amounts people report using. They are not from any study, have not been evaluated for safety, and are reproduced here only because they circulate widely and are better seen alongside the evidence than instead of it.
| Reported by | Amount | Route |
|---|---|---|
| Commonly reported | 5–20 mg daily | oral |
No published human pharmacokinetic study establishes a dose, interval, or duration for this compound. Community figures below have no trial behind them and are reports of practice, not evidence. Phase 1 has been conducted but detailed pharmacokinetics are not in the public domain, so community dosing is not derived from published data.
Handling and storage
Oral. Trial protocols used daily oral dosing.
No established route, timing, or duration outside the trials.
Side effects
The company has reported good tolerability in phase 1, which is genuine human safety data even where the detail is not published.
The theoretical class concern with amplifying neurotrophin signalling relates to pain: NGF/TrkA signalling is central to nociception, and anti-NGF antibodies are analgesic. Amplifying that pathway could plausibly increase pain sensitivity, which is a mechanistic consideration rather than a reported finding.
No long-term data exists.
Combinations
No interaction data. Combining with other compounds targeting neurotrophin or plasticity pathways is unstudied.
Research status
A legitimate development programme by Alzecure with completed phase 1 work.
The limitation for anyone assessing it independently is that most detail has come via corporate communication rather than peer-reviewed publication.
Legal status
Not approved anywhere. Investigational. Sold in research-chemical channels.
WADA status
Not specifically named on the Prohibited List. Falls under WADA class S0, which prohibits any pharmacological substance not currently approved by any governmental regulatory health authority for human therapeutic use. Treat it as prohibited in sport.
Conclusion
ACD-856 uses a sound design strategy — allosteric potentiation rather than direct agonism — against a target where direct approaches have consistently failed.
It has phase 1 human data, which puts it ahead of most of this section. It has no published efficacy data, which puts it well behind an established treatment.
Sources
- [1]ACD-856 — Trk positive allosteric modulator, preclinical and phase 1PubMed
- [2]ACD-856 clinical trial recordsClinicalTrials.gov
- [3]Neurotrophin and TrkB signalling as a therapeutic targetPubMed
- [4]WADA Prohibited List (current)WADA
Track your own ACD-856 protocol
Peppers logs your doses, models your levels from this half-life, tracks your vials and tells you when you will run out. Free on iPhone.
Reference and educational information only. Not medical advice. Nothing here diagnoses, treats, or prescribes, and nothing here is a recommendation to use any compound. The compounds described are research chemicals and are not approved for human consumption. Legal and anti-doping status change — the review date above is when these claims were last checked. Talk to a qualified clinician about anything you intend to take.